1. Scrip
  2. >>Drug Pricing

Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump

 
• By Jessica Merrill

After a conversation with President Trump, CEO Ian Read agreed to cancel price increases on 40 drugs that took effect July 1, to give the administration time to work on its blueprint for improving the health care system.

Trump_Donald_160716_1200x675

Pfizer Inc. CEO Ian Read has agreed to claw back price increases on 40 drugs after a phone conversation with President Donald Trump July 10, in what represents an extraordinary move by a big pharma to yield to pressure from the US president. Pfizer's decision to roll back the recent price increases comes a day after the president publicly shamed Pfizer on Twitter for increasing drug prices.

"Following an extensive discussion with President Trump today, Pfizer's Chairman and CEO Ian Read announced that it will defer the...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Drug Pricing

Lilly CEO Ricks Advocates Rebalancing Drug Pricing Between US And Europe

 
• By Mandy Jackson

As President Trump focuses on “most favored nation” pricing to bring down US drug costs, CEO David Ricks used Lilly’s Q2 earnings call to advocate for a slow approach to reducing the difference between US and EU drug prices.

Pharma Is Cooperating With Trump On Direct Sale To Consumers, Bourla Says

 
• By Jessica Merrill

Pfizer is in active discussions with Trump on MFN pricing and collaborating with peers on direct sales as an approach to lower drug prices, CEO Bourla said.

Most Favored Nation Pricing: Trump Ups Pressure On Voluntary Action, Clarifies Demands

 
• By Sarah Karlin-Smith

The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.

Sanofi CFO Says Direct Sales To Patients ‘Certainly Worth Considering’

 
• By Kevin Grogan

François Roger believes fixing inefficiencies is more important than playing with pricing.

More from Scrip

PTC Projects Confidence In Sephience Launch With Royalty Buyback

 
• By Manas Mishra

The company will start shipping its newly launched phenylketonuria drug within two weeks and has bought back global net sales obligations for the treatment.

Executives On The Move: Changes At The Top At Novo Nordisk Plus Other New CEOs

Flashpoint Therapeutics and Nerviano Medical Sciences (Shanghai) have new leaders, while Genmab hires an ex-Gilead Sciences executive.

Lilly Confident In Orforglipron Despite Disappointing Phase III Data

 
• By Mandy Jackson

Lilly spent much of its earnings call defending orforglipron as analysts lamented its results in obesity versus Novo’s semaglutide, overshadowing strong Q2 revenue growth driven by existing GLP-1/GIP franchise Mounjaro/Zepbound.